巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Taysha Gene Therapies

TSHA
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Taysha Gene Therapies - 延遲價格・最後更新於 21/01 12:15
最高位
8.300
最低位
7.870
開市價
--
前收市價
8.120
成交量(千)
5.44
成交額(百萬)
0.37
買入
--
賣出
--
每手股數
--
市值(百萬)
302.79
市盈率
--
息率
--
差價
--
52週高低
32.390 - 7.760
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Taysha Gene Therapies
證券代碼
TSHA.US
所屬板塊
Biotechnology
公司業務
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
發行量
37761435
公司總部
2280 Inwood Road
公司網址
https://www.tayshagtx.com
公司電話
+1 214 612-0000
暫無內容

關於

Taysha Gene Therapies(TSHA.US)所屬的行業板塊為Biotechnology。
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
詳細公司背景可參考: https://www.tayshagtx.com